The dilemma of DCIS

ArticleinThe Breast 16 Suppl 2(2):S59-62 · January 2008with6 Reads
DOI: 10.1016/j.breast.2007.07.015 · Source: PubMed
The increasingly frequent diagnosis of ductal carcinoma in situ (DCIS) presents a major clinical dilemma. Our inability to predict which DCIS will progress to invasive cancer or the time interval in which recurrent DCIS or invasive cancer will occur has resulted in treatments ranging from mastectomy to excision and observation being offered to patients. Four randomized trials have demonstrated that the use of radiation reduces the risk of local recurrence by about 50% in women with DCIS. Prospective attempts to duplicate retrospective findings that wide excision results in high rates of local control have been unsuccessful. Patient attitudes towards risks and benefits of treatment are an important component of treatment choice in the absence of predictors of biologic behavior.
  • [Show abstract] [Hide abstract] ABSTRACT: Both vendor and customer must understand what is expected in order for the relationship to be successful. Vendor report cards are a useful vehicle for providing this communication. The report cards that Northern Telecom is now receiving are customer-initiated formal rating systems that grade suppliers on customer-perceived key areas of product, service, and support performance on a regular basis. These report cards describe expectations and establish targets for vendor performance. Customer feedback is provided on a consistent basis to monitor the vendor's progress and promote continuous improvement. Through this cooperative effort, key areas for improvement can be identified and addressed to ensure optimal benefits for both the customer and the vendor
    Article · Jan 1992 · The Oncologist
  • [Show abstract] [Hide abstract] ABSTRACT: Ductal carcinoma in situ (DCIS) is the fastest growing subtype of breast cancer, mainly because of the aging of our populations and improvements in diagnostic mammography and core biopsy. DCIS represents a proliferation of malignant-appearing cells that have not invaded beyond the ductal basement membrane and is a precursor for the development of invasive breast cancer (IBC). Approximately 40% of patients with DCIS treated with biopsy alone, without complete excision or further therapy, develop IBC. Most DCIS itself is harmless if it is detected and excised before it can progress to IBC, and the current approach to DCIS treatment is aimed at just that goal. Typically, it consists of multimodal treatment including segmental mastectomy followed by radiation therapy to the whole breast and then hormonal therapy or total mastectomy followed by hormonal therapy. This review discusses the state-of-the-art in DCIS detection and treatment and highlights promising new strategies in the care of DCIS patients. The data regarding the effectiveness of breast-conserving surgery versus total mastectomy, the possible avoidance of radiation therapy in some subgroups of patients, and the role of hormonal agents are reviewed. Neoadjuvant therapy and the use of trastuzumab for DCIS are currently under investigation and may be future treatment options for DCIS.
    Full-text · Article · Dec 2007
  • Article · Dec 2010 · The Oncologist
Show more